7 completed, 2 terminated. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Zafgen, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes ZGN-1061, Placebo - Type 2 Diabetes Mellitus, Overweight and Obesity | Phase 2 | Completed | Zafgen, Inc. | 188 | 2017-09-12 | 2019-05-24 |
| An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Obesity, Type 2 Diabetes | Phase 2 | Terminated | Zafgen, Inc. | 152 | 2014-12-01 | 2016-01-06 |
| Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Prader-Willi Syndrome, Obesity | Phase 3 | Terminated | Zafgen, Inc. | 108 | 2014-09-01 | 2017-01-26 |
| An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury ZGN-440 sterile diluent, ZGN-440 for injectable suspension - Obesity, Over-weight | Phase 2 | Completed | Zafgen, Inc. | 14 | 2014-04-01 | 2016-07-18 |
| An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension - Obesity, Over-weight | Phase 2 | Completed | Zafgen, Inc. | 17 | 2013-06-01 | 2016-07-18 |
| An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects Beloranib, Placebo - Obesity | Phase 2 | Completed | Zafgen, Inc. | 160 | 2012-08-01 | 2016-07-14 |
| ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity ZGN-440, ZGN-440 sterile diluent - Obesity | Phase 1 | Completed | Zafgen, Inc. | 25 | 2011-12-01 | 2012-07-18 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers ZGN-433, Normal Saline - Obesity | Phase 1 | Completed | Zafgen, Inc. | 25 | 2011-06-01 | 2011-12-30 |
| Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers ZGN-433 - Obesity | Phase 1 | Completed | Zafgen, Inc. | 31 | 2009-12-01 | 2012-01-11 |
Obesity (9) · Overweight (5) · Diabetes Mellitus, Type 2 (2) · Prader-Willi Syndrome (2) · Craniopharyngioma (1) · Hyperphagia (1) · Weight Loss (1)
CKD732 (7) · Injections, Subcutaneous (1) · Saline Solution (1) · ZGN-1061 (1)
Australia (7) · United States (3) · New Zealand (1)
Dennis Kim, MD (3) · J K Marjason, MD (3) · James E Vath, PhD (1) · Jennifer Miller, MD (1)